WO2009096817A2 - Produit réduisant le degré d’intoxication aigue par l’alcool (d’ébriété) et procédé d'utilisation correspondant - Google Patents

Produit réduisant le degré d’intoxication aigue par l’alcool (d’ébriété) et procédé d'utilisation correspondant Download PDF

Info

Publication number
WO2009096817A2
WO2009096817A2 PCT/RU2009/000033 RU2009000033W WO2009096817A2 WO 2009096817 A2 WO2009096817 A2 WO 2009096817A2 RU 2009000033 W RU2009000033 W RU 2009000033W WO 2009096817 A2 WO2009096817 A2 WO 2009096817A2
Authority
WO
WIPO (PCT)
Prior art keywords
alcohol
intoxication
hangover
agent
degree
Prior art date
Application number
PCT/RU2009/000033
Other languages
English (en)
Russian (ru)
Other versions
WO2009096817A3 (fr
Inventor
Andrey Alexandrovich Ivashchenko
Nikolay Filippovich Savchuk
Alexander Vasilievich Ivashchenko
Original Assignee
Alla Chem, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alla Chem, Llc filed Critical Alla Chem, Llc
Publication of WO2009096817A2 publication Critical patent/WO2009096817A2/fr
Publication of WO2009096817A3 publication Critical patent/WO2009096817A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Definitions

  • the invention relates to a new tool that reduces the degree of acute alcohol intoxication (intoxication) and / or has an anti-hangover effect, a biologically active additive, a pharmaceutical composition, a drug that can weaken an alcoholic hangover caused by excessive consumption of products containing ethyl alcohol.
  • Hangover syndrome affects about 50% of the population who consume alcohol in significant doses, which causes economic damage, since during this period there is a significant decrease in human performance [Smith, S M .; Varpes, GM Sigps apd smartphones of hapgiver: rewaleps apd relatiopshir to also us and the advanced adul. Drug Alcohol Direp. 11: 249-269; 1983].
  • the economic damage associated with the deterioration of performance due to a hangover in 2000 in the United States amounted to about $ 148 billion [Wi convinced Thannnencion, JG; Shlirak, MG; Wroper, WS The alcohol hapgover. Arm.Ipterp.Med. 132: 897-902; 2000].
  • the hangover syndrome develops within a few hours after the end of acute alcohol intoxication against the background of the restoration of general motor activity, thinking and memory [Streufert, S .; Rogash, R .; Braig, D .; Gipgrireteh, D .; Kapper, A .; Lapdis, R .; Lopardi, L .; Roache, J .; Severs, W. Alcohol hapver apd maperial effestivess. Alcohol CHn. Exp Res. 19: 1141-1146; 1995. Salimov, RM; Markpa, NV; Rerelkipa, O. V .; Maskii, A. L; Rolletaeva, 1. 1.
  • a hangover condition is characterized by a complex set of subjective discomfort and impaired sensory-motor coordination, which are objectively recorded, in particular, as violation of the filtration of sensory information in the brain [Grillop, Sipha, O'Malleu, 1994; Grillop et al., 2000] and difficulty maintaining the balance of the body.
  • Violation of the filtration of sensory information and difficulty maintaining equilibrium have a homologous manifestation in humans and different types of mammals and can be measured in an animal experiment by evaluating prepulse inhibition of trembling in response to an acoustic stimulus [Maysky A.I., Salimov R.M. Guidelines for preclinical evaluation of drugs for the treatment of alcoholism.
  • dimercaprol which is an antidote for poisoning with arsenic compounds, heavy metal salts, cardiac glycosides, and also improves lipid peroxidation in the period after alcohol intoxication [US20060148898 Al. ⁇ uripg apd rorhulastis agept arrlid duri ⁇ g th Canal us founded procedure for alcohol apd psuskhoastive substapses. 2006.07.06].
  • the ability of dimercaprol to restore the processes of sensory filtration and muscle coordination disrupted by alcohol is not known.
  • contraindications that limit the use of dimercaprol include liver failure and arterial hypertension [Drug Register.
  • Dimercaprol http://www.rlsnet.ru/mnn_dimerkaprol.html; US Dearttep of Nalth & Nutrition Services. Dietersarrol, http://www.remm.nlm.gov/dimercaprol.htm].
  • These contraindications are of particular importance when dimercaprol is used in combination with alcohol, which in turn creates an additional burden on the detoxifying function of the liver and can provoke arterial hypertension [Gorelik, P. B. Alcohol apd ströke. Stroke. 18: 268-271; 1987; Tirelli, S. R .; Leope, AF; Sölho, E. B .; Resstel, L.
  • the active ingredient contains succinic acid and / or its salts, fumaric acid and / or its salts, fructose, dry extract of St. John's wort grass (Nurerisum), sources of magnesium ions and sources of potassium ions, which, when used after alcohol, can increase the time retention of animals on a rotating rod, although its ability to improve sensory filtration performance is not shown [RU2250778. An agent that reduces the adverse effects of acute alcohol intoxication. 2004.02.26]. This product does not contain the amino acids tianin and series.
  • amino acid means a natural amino acid or a non-natural amino acid.
  • Preferred amino acids are amino acids containing an ⁇ or ⁇ amino group. Examples of natural amino acids are alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, methionine, glycine, series, tianine, threonine and cysteine.
  • Bioly active additives means substances of natural origin (their concentrates, solutions, mixtures, etc.) or biologically active substances of synthetic, semisynthetic or biotechnological origin and their analogues that are free of drugs and intended for use with food or regardless of its intake, as well as for introduction into food. Supplements are used to enrich the human diet and give it special preventive and health-improving properties. Traditionally, dietary supplements are divided into three main groups: nutraceuticals, eubiotics (probiotics) and parapharmaceuticals. Parapharmaceuticals mean dietary supplements used for prophylaxis, adjuvant therapy, and maintaining the physiological boundaries of the functional activity of organs and systems. Parapharmaceuticals are organic acids, bioflavonoids, biogenic amines, alkaloids, oligosaccharides, polynucleotides, etc. Parapharmaceuticals can increase the adaptive capacity of the body in extreme conditions.
  • Medical substance (drug substance, drug substitution) means a physiologically active substance of synthetic or other (biotechnological, plant, animal, microbial and other) origin, having pharmacological activity and is the active principle of the pharmaceutical composition used for the manufacture and manufacture of a medicinal product ( facilities).
  • “Medicinal product (preparation)” a substance (or a mixture of substances in the form of a pharmaceutical composition) in the form of tablets, capsules, injections, ointments and other formulations intended to restore, correct or alter physiological functions in humans and animals, as well as for treatment and disease prevention, diagnosis, anesthesia, contraception, cosmetology and more.
  • “Therapeutic cocktail” is a simultaneously administered combination of two or more drugs with different a mechanism of pharmacological action and aimed at various biological targets involved in the pathogenesis of the disease.
  • “Pharmaceutical composition” means a composition comprising a drug substance (substance) and at least one of the components selected from the group consisting of pharmaceutically acceptable and pharmacologically compatible excipients, solvents, diluents, carriers, excipients, distributing and perceiving agents delivery vehicles such as preservatives, stabilizers, fillers, grinders, moisturizers, emulsifiers, suspending agents, thickeners, sweeteners, perfumes, flavors, anti-tank terial agents, fungicides, lubricants, prolonged delivery regulators, the choice and ratio of which depends on the nature and method of administration and dosage.
  • pharmaceutically acceptable and pharmacologically compatible excipients such as preservatives, stabilizers, fillers, grinders, moisturizers, emulsifiers, suspending agents, thickeners, sweeteners, perfumes, flavors, anti-tank terial agents, fungicides, lubricants, prolonged delivery regulators, the choice and
  • suspending agents examples include ethoxylated isostearyl alcohol, polyoxyethylene, sorbitol and sorbitol ether, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, as well as mixtures of these substances. Protection against the action of microorganisms can be achieved using a variety of antibacterial and antifungal agents, for example, parabens, chlorobutanol, sorbic acid and the like.
  • the composition may also include isotonic agents, for example, sugars, sodium chloride and the like.
  • the prolonged action of the composition can be achieved using agents that slow down the absorption of the active principle, for example, aluminum monostearate and gelatin.
  • suitable carriers, solvents, diluents and delivery vehicles are water, ethanol, polyalcohols, and also mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters (such as ethyl oleate).
  • excipients are lactose, milk sugar, sodium citrate, calcium carbonate, calcium phosphate and the like.
  • grinders and distributors are starch, alginic acid and its salts, silicates.
  • lubricants are magnesium stearate, sodium lauryl sulfate, talc, and high molecular weight polyethylene glycol.
  • the pharmaceutical composition for oral, sublingual, transdermal, intramuscular, intravenous, subcutaneous, local or rectal administration of the active principle, alone or in combination with another active principle, can be administered to animals and humans in a standard administration form, in the form of a mixture with traditional pharmaceutical carriers.
  • Suitable unit dosage forms include oral forms such as tablets, gelatin capsules, pills, powders, granules, chewing gums and oral solutions or suspensions, for example, therapeutic shakes, sublingual and buccal administration forms, aerosols, implants, local, transdermal, subcutaneous, intramuscular, intravenous, intranasal or intraocular administration forms and rectal forms introduction.
  • “Pharmaceutically acceptable salt” means the relatively non-toxic organic and inorganic salts of the acids and bases of the present invention. These salts can be prepared in situ during the synthesis, isolation or purification of compounds or prepared specially. In particular, base salts can be prepared specifically based on the purified free base of the claimed compound and a suitable organic or inorganic acid.
  • salts thus obtained are hydrochlorides, hydrobromides, sulfates, bisulfates, phosphates, nitrates, acetates, oxalates, valeriates, oleates, palmitates, stearates, laurates, borates, benzoates, lactates, tosylates, citrates, maleates, fumarates, succinates, tartrates mesylates, malonates, salicylates, propionates, ethanesulfonates, benzenesulfonates, sulfamates and the like.
  • Salts of the claimed acids can also be specially prepared by reacting the purified acid with a suitable base, and metal and amine salts can be synthesized.
  • Metal salts include sodium, potassium, calcium, barium, zinc, magnesium, lithium and aluminum salts, the most desirable of which are sodium and potassium salts.
  • Suitable inorganic bases from which metal salts can be obtained are hydroxide, carbonate, sodium bicarbonate and hydride, potassium hydroxide and bicarbonate, potash, lithium hydroxide, calcium hydroxide, magnesium hydroxide, zinc hydroxide.
  • amines and amino acids are selected that are sufficiently basic to form a stable salt and are suitable for medical use (in particular, they should have low toxicity).
  • amines include ammonia, methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, benzylamine, dibenzylamine, dicyclohexylamine, piperazine, ethylpiperidine, tris (hydroxymethyl) aminomethane and the like.
  • tetraalkylammonium hydroxides for example, such as choline, tetramethylammonium, tetraethylammonium and the like, can be used for salt formation.
  • amino acids can be used basic amino acids - lysine, ornithine and arginine.
  • composition of the new CCEF together with a natural, synthetic or semi-synthetic polymer suitable for oral administration further reduces the degree of acute alcohol intoxication (intoxication).
  • the purpose of this invention is to create a new tool, biologically active additives, pharmaceutical compositions and medicines that reduce the degree of acute alcohol intoxication (intoxication) and / or have anti-hangover effects and are able to weaken the alcohol hangover caused by excessive consumption of products containing ethyl alcohol.
  • This goal is achieved by a means with anti-hangover, containing as active components L-serine, tianine and fructose and / or a polymer suitable for oral administration, in a mass ratio of (12-18): (0.8-l, 2): (40-60) :( 0-14), respectively.
  • an agent that reduces the degree of acute alcohol intoxication (intoxication) and has an anti-hangover effect containing as active components L-serine, L-tianine, fructose and a natural, synthetic or semi-synthetic polymer suitable for oral administration in the ratio (12- 18) :( 0,8-l, 2) :( 40-60) :( 8-14), respectively.
  • a natural, synthetic or semi-synthetic polymer suitable for oral administration is used, for example, cellulose derivatives, starch derivatives (in particular hydroxyethyl starch), gelatin and its derivatives, dextran, polyvinylpyrrolidone, chitosan, cyclodextrins, , agar, guar gum and several others.
  • the subject of this invention is also a biologically active additive comprising an agent that reduces the degree of acute alcohol intoxication (intoxication) and has an anti-hangover effect, containing, as active components, L-serine, fructose, tianine and / or a polymer suitable for oral administration.
  • a more preferred biologically active additive includes an agent that reduces the degree of acute alcohol intoxication (intoxication) and / or has an anti-hangover effect, containing L-serine, tianine, fructose, and / or a polymer suitable for oral administration in a weight ratio of ( 12-18) :( 0.8-1.2) :( 40-60) :( 0-14), respectively.
  • a dietary supplement may include diluents, auxiliary agents and / or carriers.
  • a dietary supplement along with the agent of the present invention may include other active agents and / or dietary supplements, provided that they do not cause undesirable effects, for example, allergic reactions.
  • the subject of this invention is also a pharmaceutical composition that reduces the degree of acute alcohol intoxication (intoxication) and / or has an anti-hangover effect, containing L-serine, tianine, fructose and / or a polymer suitable for oral administration and an inert excipient and / or solvent.
  • a more preferred pharmaceutical composition having an anti-hangover effect contains L-serine, tianine, fructose and / or a polymer suitable for oral administration in a weight ratio of (12-18): (0.8-l, 2) :( 40-60 ) :( 0-14), respectively, and an inert filler and / or solvent.
  • the pharmaceutical composition may include pharmaceutically acceptable excipients.
  • pharmaceutically acceptable excipients are meant diluents, excipients and / or carriers used in the pharmaceutical field.
  • the pharmaceutical composition along with the agent of the present other active agents may also be included in the invention, provided that they do not cause undesirable effects, for example, allergic reactions.
  • Carriers which are used in the pharmaceutical field to produce oral forms of a medicinal product are binders, lubricants, disintegrants, solvents, diluents, stabilizers, suspending agents, colorless agents, flavoring agents; antiseptic agents, solubilizers, stabilizers are used in injection forms of the drug; in local forms of the drug, bases, diluents, lubricants, antiseptic agents are used.
  • the aim of the present invention is also a method for producing a pharmaceutical composition.
  • the goal is achieved by mixing the means of the present invention with an inert filler and / or solvent.
  • This goal is also achieved by dissolving the agent in water, freeze drying the resulting solution and mixing the resulting composition with an inert filler and / or solvent.
  • the subject of this invention is also a medicament in the form of tablets, capsules or injections, placed in a pharmaceutically acceptable package, comprising an agent or a new pharmaceutical composition intended to reduce the degree of acute alcohol intoxication (intoxication) and / or the reduction of alcohol hangover caused by excessive consumption of products containing ethyl alcohol.
  • the drug may be administered orally.
  • the clinical dosage can be adjusted depending on: therapeutic efficacy and bioavailability of the active ingredients in the body, their metabolic rate and excretion from the body, and also depending on the patient’s age, gender and stage of illness. In accordance with the instructions of a doctor or pharmacist, these drugs can be taken several times during certain periods of time (preferably from one to six times).
  • FIG. 1 the influence of 25% ethyl alcohol on locomotor activity (time spent in the center and in the arms of the closed cruciform labyrinth until the mice made 12 visits to the arms) of male SHK mice when they were given a dose of 4.5 g / kg inside 1.5 or 3 hours before the test. * - difference from the group receiving placebo (sterile water); FIG.
  • FIG. 3 the effect of 25% ethanol on the retention time of male SHK mice on a rotating rod when they introduced a dose of 4.5 g / kg 3 hours before the test, (initial rotation speed 5 rpm, acceleration 0.5 rpm every 10 seconds).
  • FIG. 4 the effect of 25% ethyl alcohol on prepulse inhibition of flinching in response to an acoustic stimulus, when a dose of 4.5 g / kg was administered to male SHK mice 3 hours before the test.
  • * - difference from the placebo group sterile water.
  • Example 1 A study of the effectiveness of anti-hangover and the ability to weaken the alcohol hangover of a new drug and drug, based on it, was carried out in comparison with the reference drug (dimercaprol) in experiments on male SHK mice.
  • the subnarcotic dose of alcohol was determined when administered orally (re ments), using a probe, in the form of a 25% solution of ethyl alcohol, which turned out to be 4.5 g / kg for the used mouse line and the termination period of acute intoxication (intoxication), which started about 3 hours after the introduction of alcohol.
  • 10 SHK mice were used.
  • mice A study of the effect of the new agent on hangover indicators in mice was carried out in comparison with the closest competitor, the well-known drug dimercaprol in a therapeutic dose of 4.2 mg / kg.
  • a subnarcotic dose of alcohol of 4.5 g / kg in the form of a 25% solution of ethyl alcohol was injected into the mice using a probe inside (re-s) 3 hours before the tests used.
  • Dimercaprol, series, tianin, fructose and mixtures of serine, tianin and fructose were administered orally 2.5 hours after the introduction of alcohol. In each group, 10 SHK mice were used.
  • the table shows the test data on the effect of funds on hangover indicators in mice 2.5 hours after the administration of 4500 mg / g of alcohol to male SHK mice.
  • the hangover impaired inhibition of trembling by an acoustic stimulus was estimated in%.
  • the hangover of coordination of mouse movements was evaluated by the duration of retention on a rotating rod.
  • the new drug, composition and drug based on it are more preferable compared to the known drug dimercaprol, because they do not have contraindications (liver function insufficiency and hypertension, especially when dimercaprol is used in combination with alcohol), characteristic of the latter [Register medicines. Dimercaprol, http://www.rlsnet.ru/in ⁇ i_dimerkaprol.html; U.S. Dearttep of Nalth & Nutap Servises. Dietersarrol, http://www.remm.nlm.gov/dimercaprol.htm. Gorelisk, P. B. Alcohol apd stroke. Stroke. 18: 268-271; 1987; Tirelli, S.
  • Example 2 At the beginning of the experiments, a sub-narcotic dose of alcohol was determined when it was introduced in the form of a 25% solution of ethyl alcohol using a probe inside (re works), which turned out to be 4.5 g / kg for the used mouse line, the beginning of the period of acute intoxication (intoxication) , which was observed approximately 2 hours after the introduction of alcohol, and the period of termination of acute intoxication, which began approximately 3 hours after the introduction of alcohol. The experiments were carried out on male SHK mice.
  • the assessment of acute alcohol intoxication was carried out 2 hours after the introduction of the indicated dose of alcohol according to the criterion of gross movement disorders - by the ability to stay on a rotating rod, as well as by slowing down the study of the cruciform maze by mice.
  • the mouse was placed in a Rotamex-5 installation ( ⁇ olutbus Ipstrupts, USA) on a rod, which first rotated at a speed of 5 rpm and accelerated rotation by 0.5 rpm every 10 seconds.
  • the mouse was placed in the central compartment of the labyrinth and, in a semi-automatic mode, the sequence of its transitions from one sleeve to the other was recorded. The time during which 12 such transitions occurred was recorded.
  • mice were injected into the esophagus with one of the following formulations in a volume of 10 ml / kg: 1) sterilized water, 2) 25% solution of ethyl alcohol, 3) 25% solution of ethyl alcohol + dextran (85 mg / kg), 4 ) 25% solution of ethyl alcohol + IIK-1 composition, including dextran (85 mg / kg), tianine (10 mg / kg) and series (100 mg / kg), + fructose (500 mg / kg), 5) 25% ethanol solution + PC composition, including dextran (140 mg / kg), tianine (10 mg / kg) and series (100 mg / kg), + fructose (500 mg / kg); 6) 25% solution of ethyl alcohol + Alkoklin mixture, including tianine (10 mg / kg), series (100 mg / kg) and fructose (500 mg / kg).
  • Symptoms of an alcoholic hangover observed 3 hours after the introduction of alcohol, are characterized by a violation of the filtering ability of the brain (impaired prepulse inhibition of the startle reaction to sound) and fine coordination of movements necessary to maintain balance (reducing the duration of retention on a rotating rod).
  • Dextran during alcohol intoxication does not affect retention on a rotating rod and improves the speed of movement in the maze, and in the hangover period does not affect the studied parameters.
  • Composition IIK-1 during alcohol intoxication does not affect retention on a rotating rod and improves the speed of movement in the maze, and in the hangover period improves prepulse inhibition of trembling and retention on a rotating rod.
  • Composition PC during alcohol intoxication improves retention on a rotating rod and improves the speed of movement in the maze, and in the hangover period improves prepulse inhibition of trembling and retention on a rotating rod.
  • composition "Alkocline” when administered simultaneously with alcohol during alcohol intoxication does not affect the retention on the rotating rod and the speed of movement in the labyrinth, and in the hangover - does not affect prepulse inhibition of trembling and retention on the rotating rod.
  • the composition “Alkoklin”, when administered 30 minutes before the start of the functional test during alcohol intoxication does not affect the retention on the rotating rod and the speed of movement in the maze, and in the hangover it improves prepulse inhibition of trembling and retention on the rotating rod.
  • Example 3 Obtaining biologically active additives. Thoroughly mix L-serine, L-tianine and fructose in a weight ratio of 15: 1: 50. The resulting powdery mixture is packaged in 300 mg in a suitable size gelatin capsule.
  • Example 4. Obtaining a drug in the form of tablets. 1600 mg of starch, 1600 mg of ground lactose, 400 mg of talc and 1000 mg of a mixture of L-serine, L-thianine and fructose are mixed in a weight ratio of 15: 1: 50 and pressed into a block. The resulting bar is crushed into granules and sieved through sieves, collecting granules with a size of 14-16 mesh. The granules obtained are tabletted into a suitable tablet form weighing 560 mg each.
  • Example 5 Obtaining biologically active additives.
  • 0.14 g of a natural, synthetic or semi-synthetic polymer suitable for oral administration for example, dextran, 0.10 g of L-serine, 0.01 g of tianine and 0.50 g of fructose are dissolved in 14 ml of distilled water. The resulting solution was incubated for 20 minutes at room temperature, filtered and dried, for example, in a freeze dryer. The resulting powder mixture is packaged in 300 mg in a suitable size gelatin capsule.
  • Example 6 Obtaining funds in the form of a drink.
  • 1.4 g of a natural, synthetic or semi-synthetic polymer suitable for oral administration, for example, dextran, 1.0 g of L-serine, 0.1 g of tianine and 5.0 g of fructose are dissolved in 140 ml of distilled water.
  • the resulting solution was incubated for 20 minutes at room temperature, filtered and dried, for example, in a freeze dryer.
  • the resulting powdery mixture is dissolved in water, flavoring agents, for example citric acid, are added if necessary, and the beverage is used in an effective amount.
  • the invention can be used in medicine, veterinary medicine, biochemistry.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L’invention concerne un nouveau produit réduisant le degré d’intoxication aigue par l’alcool (d’ébriété) et possédant une action « anti-gueule de bois », un additif bioactif, une composition pharmaceutique, un médicament capable de réduire l’effet « gueule de bois » provoqué par l’abus de l’alcool.
PCT/RU2009/000033 2008-01-31 2009-01-29 Produit réduisant le degré d’intoxication aigue par l’alcool (d’ébriété) et procédé d'utilisation correspondant WO2009096817A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2008103155/04A RU2358723C1 (ru) 2008-01-31 2008-01-31 Средство, обладающее антипохмельным действием, биологически активная добавка, фармацевтическая композиция, лекарственное средство и способ получения
RU2008103155 2008-01-31

Publications (2)

Publication Number Publication Date
WO2009096817A2 true WO2009096817A2 (fr) 2009-08-06
WO2009096817A3 WO2009096817A3 (fr) 2009-09-24

Family

ID=40913450

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2009/000033 WO2009096817A2 (fr) 2008-01-31 2009-01-29 Produit réduisant le degré d’intoxication aigue par l’alcool (d’ébriété) et procédé d'utilisation correspondant

Country Status (2)

Country Link
RU (1) RU2358723C1 (fr)
WO (1) WO2009096817A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2557960C1 (ru) * 2014-07-01 2015-07-27 Аллан Герович Бениашвили Ородисперсная таблетка дегидроэпиандростерона и/или комбинации дегидроэпиандростерона и l-тианина

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004165A1 (fr) * 1987-10-19 1989-05-18 Haklitch Joseph A Complement alimentaire de desintoxication
US5585467A (en) * 1990-12-04 1996-12-17 Il-Yang Pharmaceutical Co., Ltd. Proteoglycan(G009) effective in enhancing antitumor immunity
RU2160589C1 (ru) * 2000-05-18 2000-12-20 Алекс Кашлинский Средство для снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома и способ снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома с использованием этого средства
CA2453159A1 (fr) * 2001-07-10 2003-01-23 Penam Investments Pty Ltd Preparation et ses utilisations pour combattre la xylostomiase
US20070213400A1 (en) * 2004-05-06 2007-09-13 Taiyokagaku Co., Ltd. Alcohol-metabolism enhancing composition and ingesta containing the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004165A1 (fr) * 1987-10-19 1989-05-18 Haklitch Joseph A Complement alimentaire de desintoxication
US5585467A (en) * 1990-12-04 1996-12-17 Il-Yang Pharmaceutical Co., Ltd. Proteoglycan(G009) effective in enhancing antitumor immunity
RU2160589C1 (ru) * 2000-05-18 2000-12-20 Алекс Кашлинский Средство для снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома и способ снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома с использованием этого средства
CA2453159A1 (fr) * 2001-07-10 2003-01-23 Penam Investments Pty Ltd Preparation et ses utilisations pour combattre la xylostomiase
US20070213400A1 (en) * 2004-05-06 2007-09-13 Taiyokagaku Co., Ltd. Alcohol-metabolism enhancing composition and ingesta containing the same

Also Published As

Publication number Publication date
RU2358723C1 (ru) 2009-06-20
WO2009096817A3 (fr) 2009-09-24

Similar Documents

Publication Publication Date Title
RU2573990C2 (ru) Препарат, содержащий аминокислоты и растения, и его активность при алкогольной детоксикации
CN106456583B (zh) 用于治疗神经障碍的巴氯芬、阿坎酸和中链甘油三酯的组合
CZ20033066A3 (cs) Kapalná farmaceutická směs
RU2501808C1 (ru) Композиция для улучшения функции мозга и способ улучшения функции мозга
JP2002544241A (ja) 生体活性剤の改良された細胞取り込み
IE903717A1 (en) S(+)-ibuprofen-L-amino acid and S(+)-ibuprofen-D-amino acid as onset hastened enhanced analgesics
HU230031B1 (hu) Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
CA2891362C (fr) Comprime effervescent
RU2396076C1 (ru) Средство, уменьшающее степень острой алкогольной интоксикации (опьянения) и обладающее антипохмельным действием, биологически активная добавка, фармацевтическая композиция, лекарственное средство и способ получения
WO2005102320A1 (fr) Medicament pour traiter des infections virales
JPS5938203B2 (ja) 補酵素ｑを主成分とする脳循環障害治療剤
RU2358723C1 (ru) Средство, обладающее антипохмельным действием, биологически активная добавка, фармацевтическая композиция, лекарственное средство и способ получения
RU2240784C1 (ru) Лекарственное средство на основе арбидола
WO2022103639A1 (fr) Méthodes de traitement de maladies auto-immunes ou inflammatoires avec du cannabidiol ou ses dérivés/analogues
JP2018188377A (ja) 医薬組成物
US8344101B2 (en) Composition for improving brain function and method for improving brain function
WO2007107835A2 (fr) Formulations liquides stables d'agents anti-epileptiques
WO2012036191A1 (fr) Composition destinée à l'amélioration de la fonction cérébrale et méthode d'amélioration de la fonction cérébrale
TW201216977A (en) Compositions and methods for improving brain function
JP7291380B2 (ja) 鼻水又は鼻づまりの口腔粘膜投与用即効性改善剤
RU2276982C2 (ru) Средство, обладающее противовоспалительным, анальгетическим, жаропонижающим действием в форме таблетки
EP1518554B1 (fr) Composition pharmaceutique pour le traitement de l'hyperhomocystéinémie
UA126659C2 (uk) Фармацевтичний склад, що містить бензокаїн з посиленою стабільністю
US8343924B2 (en) Composition for improving brain function and method for improving brain function
CN111166868A (zh) 一种用于治疗神经疾病和障碍的组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09706073

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09706073

Country of ref document: EP

Kind code of ref document: A2